UPDATE: Evercore ISI Downgrades Cepheid (CPHD) to Sell; Analyst Sees Risk of Multiple Compression
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Wedbush Cuts Price Target to $66 on Cepheid (CPHD) Following 2Q15
July 24, 2015 10:13 AM EDTWedbush reiterated an Outperform rating on Cepheid (NASDAQ: CPHD), and cut the price target to $66.00 (from $67.00), following 2Q15 results. CPHD reported 2Q15 sales of $133 MM compared to $131 MM estimates. Reported GAAP EPS was ($0.23), compared with consensus EPS loss of ($0.21).
Analyst Zarak Khurshid commented,... More
Needham & Company Raises Price Target to $70 on Cepheid (CPHD) Following 2Q15
July 24, 2015 7:34 AM EDTNeedham & Company reiterated a Buy rating on Cepheid (NASDAQ: CPHD), and raised the price target to $70.00 (from $66.00), following 2Q15 results. Revenue was $132.5M vs. consensus of $130.5M. Non-GAAP EPS was reported at ($0.23) vs. consensus of ($0.21).
Analyst Mike Matson commented, "CPHD's 2Q15 revenue beat... More
Cepheid (CPHD) PT Raised to $72 at MKM Partners
July 24, 2015 7:22 AM EDTMKM Partners analyst Peter Lawson reiterated a Buy rating and boosted his price target on Cepheid (NASDAQ: CPHD) to $72.00 (from $65.00) following Q2 results.
Lawson commented, "We are reiterating our Buy rating and raising our PT to $72 following 2Q results. CPHD beat... More
Cepheid (CPHD) Tops Q2 EPS by 15c
July 23, 2015 4:41 PM EDTCepheid (NASDAQ: CPHD) reported Q2 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $132.5 million versus the consensus estimate of $130.7 million.
For earnings history and earnings-related data on Cepheid (CPHD) click here.
... More